3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Basal Cell
3
Margins of Excision
2
Barrett Esophagus
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Cyst
1
Nevus, Pigmented
1
Nephrolithiasis
1
Multicystic renal dysplasia, bilateral
1
Melanoma
1
Lung Neoplasms
1
Lung Diseases
1
Hematuria
1
Esophageal Neoplasms
1
Benign Neoplasm of Liver and/or Biliary Ducts
1
Adenocarcinoma
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
29
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Radiotherapy
14
Nivolumab
12
Ramucirumab
11
Cyclophosphamide
11
Trastuzumab
8
Erlotinib Hydrochloride
8
Taxes
7
Radiosurgery
7
Drug Therapy
7
cemiplimab
6
zolbetuximab
5
trastuzumab deruxtecan
5
regorafenib
5
durvalumab
5
Sorafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma
×
Microscopy, Confocal
×
Clear all
NCT07541911
2026-05-18
LaserSAFE
University College, London
Phase NA
Recruiting
693 enrolled